Combinations of heparin cofactor ii agonist and platelet iib/iiia antagonist, and uses thereof
CA 2440557 C · Owner: Intimax Corporation · Inventors: Cardin, Alan D.; Van Gorp, Cornelius L.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Combined use of a heparin cofactor II agonist and a platelet GPIIb/IIIa receptor antagonist to inhibit both platelet aggregation and thrombin generation resulting from disease, injury or responses to wound repairs. The combined use of the heparin cofactor II agonist and the platelet GPIIb/IIIa receptor antagonist can achieve these therapeutic benefits while at the same time minimizing or reducing the risk of hemorrhagic side effects (e.g. prolonged bleeding) and without causing undesired antigenic responses. Moreover, certain subtherapeutic amounts of a platelet GPIIb/IIIa receptor antagonist can, in combination, be therapeutically effective in inhibiting both platelet aggregation …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 7, 2002 and granted April 19, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 7, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 7, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.